A Fully Decentralized Randomized Controlled Study of As-Needed Albuterol–Budesonide Fixed-Dose Inhaler in Mild Asthma: The BATURA Study Design
BATURA evaluates as-needed albuterol-budesonide in participants with mild asthma. The decentralized study model enables the trial to move out of research sites into participant homes, reducing participant burden and improving access.
Authors
- Lynn Dunsire
- Frank C. Albers (ORCID: https://orcid.org/0000-0001-7039-4621)
- Christy Cappelletti (ORCID: https://orcid.org/0000-0002-7203-7721)
- Anna Danilewicz
- Mark E. Cooper (ORCID: https://orcid.org/0000-0002-5953-642X)
- Craig LaForce
- Robert C. Rees
Institutions
- AstraZeneca (United Kingdom) (GB)
- Clinical Tools, Inc. (US)
- AstraZeneca (United States) (US)
- North Carolina Clinical Research (US)
- Avillion (United Kingdom) (GB)
Publication Details
- Journal
- Journal of Asthma and Allergy
- Published
- 2024-08-01
- DOI
- https://doi.org/10.2147/jaa.s471134
- Citations
- 6
- Primary Topic
- Inhalation and Respiratory Drug Delivery
- Type
- article
- Field-Weighted Citation Impact
- 2.51
Funders
- AstraZeneca